Adam's Take By Adam Feuerstein Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock
Adam's Take By Adam Feuerstein Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval
Adam's Take By Adam Feuerstein A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling
Adam's Take By Adam Feuerstein The bearish view of Acadia Pharma’s antipsychotic drug takes a hit with positive trial results
Adam's Take By Adam Feuerstein Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share
Adam's Take By Adam Feuerstein Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person
Adam's Take By Adam Feuerstein FDA’s Sarepta rejection is rooted in the past, and will weigh on its future
Adam's Take By Adam Feuerstein This troubled biotech needed cash, so it turned to a predatory lender: its own CEO
Adam's Take By Adam Feuerstein Sarepta’s bad week raised questions about its gene therapy program. Here are some answers
Adam's Take By Adam Feuerstein Show us the data: Bluebird raises questions by sitting on results of CAR-T drug critical to its future
Adam's Take By Adam Feuerstein With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug
Adam's Take By Adam Feuerstein The FDA erred in approving new women’s libido drug; don’t reward Palatin Technologies
Adam's Take By Adam Feuerstein Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk
Adam's Take By Adam Feuerstein Sales of Amarin’s heart drug are surging, but the stock not so much. Here’s why
Adam's Take By Adam Feuerstein Taking the measure of small-cap biotech: ResTORbio, Trovagene, Atossa Genetics
Biotech By Adam Feuerstein Biogen-Eisai partnership may be hitting a rough patch following Alzheimer’s drug blowup
Adam's Take By Adam Feuerstein Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said
Adam's Take By Adam Feuerstein Suddenly, the Bristol-Celgene deal is looking shaky. What might be next for Celgene?
Adam's Take By Adam Feuerstein Wait … what? MannKind posts best-ever quarter of inhaled insulin product sales
Adam's Take By Adam Feuerstein Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes
Adam's Take By Adam Feuerstein Taking the measure of small-cap biotech: Fennec Pharma, Actinium Pharma
Adam's Take By Adam Feuerstein What’s next in NASH? 6 things to know following the failure of Gilead’s lead drug for fatty liver disease
Adam's Take By Adam Feuerstein Taking the measure of small-cap biotech: Bellus Health, OncoSec Medical
Adam's Take By Adam Feuerstein Gilead’s new CEO hasn’t shown up for work yet, leaving the biotech rudderless, investors anxious
Biotech By Adam Feuerstein Aurinia’s flop in dry-eye trial brings an unexpected victory — and a shot at challenging Allergan
Adam's Take By Adam Feuerstein Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher
